CONTRAINDICATIONS

SURGIFLO® should not be used in instances of pumping arterial hemorrhage. SURGIFLO® will not act as a tampon or plug in a wound. When control of bleeding by ligature or other conventional methods is ineffective or impractical.

INTENDED USE/INDICATIONS

When used in appropriate amounts SURGIFLO® is absorbed completely within 4 to 6 weeks.

ACTIONS

SURGIFLO® Hemostatic Matrix Kit is simply introduced into a wound area by: stabbing, perforation, or cutting the sterile tab, then inserting the product inside the wound area.

ADVERSE EVENTS

SURGIFLO® should not be used in conjunction with methylmethacrylate adhesives.

SURGIFLO® is supplied as a sterile product and cannot be resterilized.

SURGIFLO® should not be used for controlling post-partum intrauterine bleeding or menorrhagia.

SURGIFLO® should be removed from the site of application when used in, around, or in proximity to foramina in bone, areas of bone repair, or areas where non-surgical procedures are performed.

Affiliates of ETHICON, Inc. and/or its designated representatives may make use of the above as part of their communication with healthcare providers, and may also be used in commerce where being presented to or made available to patients, and used as a trade reference or in reference to the product or product information.

© 2018 Ethicon US, LLC. All rights reserved. 037530-181105
Do not inject SURGIFLO® Hemostatic Matrix Kit into blood vessels. See the Contraindications, Warnings, and Precautions. For complete product details, see instructions for use. For technical support, call 1-877-ETHICON. Call 1-800-255-2500 to order.